BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22465923)

  • 1. [Appropriate pharmacotherapy in patients with chronic kidney disease - new approach - ].
    Hirata S
    Yakugaku Zasshi; 2012; 132(4):461-70. PubMed ID: 22465923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
    Verbeeck RK; Musuamba FT
    Eur J Clin Pharmacol; 2009 Aug; 65(8):757-73. PubMed ID: 19543887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug dosing guidelines in patients with renal failure.
    Swan SK; Bennett WM
    West J Med; 1992 Jun; 156(6):633-8. PubMed ID: 1615656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic changes in renal failure].
    Launay-Vacher V; Storme T; Izzedine H; Deray G
    Presse Med; 2001 Mar; 30(12):597-604. PubMed ID: 11317921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of drug administration in renal insufficiency.
    Lam YW; Banerji S; Hatfield C; Talbert RL
    Clin Pharmacokinet; 1997 Jan; 32(1):30-57. PubMed ID: 9012555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safe drug prescribing for patients with renal failure].
    Tanaka A; Shimizu H; Matsuo S
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():58-66. PubMed ID: 18074518
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacokinetics of anesthesia related drugs in patients with chronic kidney disease].
    Tsubokawa T
    Masui; 2013 Nov; 62(11):1293-303. PubMed ID: 24364270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal failure, drug pharmacokinetics and drug action.
    Fabre J; Balant L
    Clin Pharmacokinet; 1976; 1(2):99-120. PubMed ID: 13956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quantitative approach to drug dosing in chronic kidney disease.
    Olyaei AJ; Steffl JL
    Blood Purif; 2011; 31(1-3):138-45. PubMed ID: 21228582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug pharmacokinetics in renal failure: What's new?].
    Naud J; Dumayne C; Nolin TD; Leblond FA; Pichette V
    Nephrol Ther; 2015 Jun; 11(3):144-51. PubMed ID: 25861715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.
    Tortorici MA; Cutler DL; Hazra A; Nolin TD; Rowland-Yeo K; Venkatakrishnan K
    J Clin Pharmacol; 2015 Mar; 55(3):241-50. PubMed ID: 25501531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.
    Sayama H; Takubo H; Komura H; Kogayu M; Iwaki M
    AAPS J; 2014 Sep; 16(5):1018-28. PubMed ID: 24912798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.
    Naud J; Michaud J; Beauchemin S; Hébert MJ; Roger M; Lefrancois S; Leblond FA; Pichette V
    Drug Metab Dispos; 2011 Aug; 39(8):1363-9. PubMed ID: 21525170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs in renal failure: dosing guidelines for frequently used drugs in end-stage renal disease and dialysis patients.
    Seyffart G
    Blood Purif; 1985; 3(1-3):140-68. PubMed ID: 4096834
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing pediatric dosing: a developmental pharmacologic approach.
    Anderson GD; Lynn AM
    Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases.
    Liu B; Luo F; Luo X; Duan S; Gong Z; Peng J
    Curr Drug Metab; 2018; 19(7):568-576. PubMed ID: 29299983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
    Khanal A; Peterson GM; Castelino RL; Jose MD
    Intern Med J; 2014 Jun; 44(6):591-6. PubMed ID: 24946814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.